CL2011002171A1 - Compuestos derivados de benzotiazinas, inhibidores de 11beta-hsd1; metodo de preparacion; composiciones farmaceuticas; y su uso para el tratamiento de la diabetes tipo 2, obesidad, dislipidemia, hipertension arterial, ateroesclerosis y ciertos tipos de cáncer. - Google Patents

Compuestos derivados de benzotiazinas, inhibidores de 11beta-hsd1; metodo de preparacion; composiciones farmaceuticas; y su uso para el tratamiento de la diabetes tipo 2, obesidad, dislipidemia, hipertension arterial, ateroesclerosis y ciertos tipos de cáncer.

Info

Publication number
CL2011002171A1
CL2011002171A1 CL2011002171A CL2011002171A CL2011002171A1 CL 2011002171 A1 CL2011002171 A1 CL 2011002171A1 CL 2011002171 A CL2011002171 A CL 2011002171A CL 2011002171 A CL2011002171 A CL 2011002171A CL 2011002171 A1 CL2011002171 A1 CL 2011002171A1
Authority
CL
Chile
Prior art keywords
pharmaceutical compositions
type
dyslipidemia
obesity
diabetes
Prior art date
Application number
CL2011002171A
Other languages
English (en)
Inventor
Michel Perez
Marie Lamothe
Didier Junquero
Yves Rival
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of CL2011002171A1 publication Critical patent/CL2011002171A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

COMPUESTOS QUE TIENEN LA FÓRMULA GENERAL (1) DONDE R 1 , R2 , R3, R4 Y R'4 SE DEFINEN TAL COMO EN LA MEMORIA DESCRIPTIVA. MÉTODOS PARA LA PREPARACIÓN DE COMPUESTOS DE FÓRMULA GENERAL (1), DONDE <strong>A</strong>1 , R2 , R3, R4 Y R' 4 E INTERMEDIARIOS SE DEFINEN DE ACUERDO A LA MEMORIA DESCRIPTIVA. COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN, COMO INGREDIENTE ACTIVO, POR LO MENOS UN COMPUESTO DE FÓRMULA GENERAL (1), EN COMBINACIÓN CON UN PORTADOR FARMACÉUTICAMENTE ACEPTABLE, COMO FÁRMACOS. USO DE DICHAS COMPOSICIONES FARMACÉUTICAS PARA PREPARAR MEDICAMENTOS ÚTILES TANTO PARA EL TRATAMIENTO CURATIVO COMO PREVENTIVO DE LA DIABETES TIPO 2; DE TRASTORNOS RELACIONADOS CON LA 11 —HIDROXIESTEROIDE DESHIDROGENASA TIPO 1 (11HSD1); O DE LA OBESIDAD; DISLIPIDEMÍA; HIPERTENSIÓN ARTERIAL; ATEROESCLEROSIS Y PATOLOGÍAS CLÍNICAS QUE SON CONSECUENCIA DE LAS ANTERIORES, TALES COMO ACCIDENTE CEREBROVASCULAR CORONARIO, ACCIDENTE CEREBROVASCULAR, O ARTERITIS DE LOS MIEMBROS INFERIORES; O HIPERGLICEMIA; INTOLERANCIA A LA GLUCOSA; INSULINORRESISTENCIA; HIPERTRIGLICERIDEM IA; HIPERCOLESTEROLEM ¡A; RESTENOSIS; O PANCREATITIS; RETINOPATÍAS; NEFROPATÍAS; NEUROPATÍAS; O CIERTOS TIPOS DE CÁNCER O GLAUCOMAS.
CL2011002171A 2009-03-03 2011-09-02 Compuestos derivados de benzotiazinas, inhibidores de 11beta-hsd1; metodo de preparacion; composiciones farmaceuticas; y su uso para el tratamiento de la diabetes tipo 2, obesidad, dislipidemia, hipertension arterial, ateroesclerosis y ciertos tipos de cáncer. CL2011002171A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0951336A FR2942797B1 (fr) 2009-03-03 2009-03-03 Derives de benzothiazines, leur preparation et leur application a titre de medicaments

Publications (1)

Publication Number Publication Date
CL2011002171A1 true CL2011002171A1 (es) 2012-04-13

Family

ID=40790339

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002171A CL2011002171A1 (es) 2009-03-03 2011-09-02 Compuestos derivados de benzotiazinas, inhibidores de 11beta-hsd1; metodo de preparacion; composiciones farmaceuticas; y su uso para el tratamiento de la diabetes tipo 2, obesidad, dislipidemia, hipertension arterial, ateroesclerosis y ciertos tipos de cáncer.

Country Status (29)

Country Link
US (1) US9187438B2 (es)
EP (1) EP2403840B1 (es)
JP (1) JP5650139B2 (es)
KR (1) KR101701531B1 (es)
CN (1) CN102341379B (es)
AR (1) AR075777A1 (es)
AU (1) AU2010220335B2 (es)
BR (1) BRPI1010243A2 (es)
CA (1) CA2753630C (es)
CL (1) CL2011002171A1 (es)
CO (1) CO6501175A2 (es)
ES (1) ES2483516T3 (es)
FR (1) FR2942797B1 (es)
GE (1) GEP20135832B (es)
HK (1) HK1165802A1 (es)
IL (1) IL214907A (es)
MA (1) MA33138B1 (es)
MX (1) MX2011008942A (es)
MY (1) MY160819A (es)
NZ (1) NZ595276A (es)
PL (1) PL2403840T3 (es)
RU (1) RU2523791C2 (es)
SA (1) SA110310181B1 (es)
SG (1) SG174208A1 (es)
TN (1) TN2011000429A1 (es)
TW (1) TWI495636B (es)
UA (1) UA105040C2 (es)
WO (1) WO2010100139A1 (es)
ZA (1) ZA201107104B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
CN103275035B (zh) * 2013-06-28 2014-11-26 安徽中医学院 苯并噻嗪类化合物、其制备方法及其抗肿瘤用途
CN103304513B (zh) * 2013-06-28 2015-02-04 安徽中医学院 一类1,2-苯并噻嗪类化合物、制备方法及其应用
CN103271923B (zh) * 2013-06-28 2014-11-26 安徽中医学院 一种苯并噻嗪衍生物的医药用途
FR3035326B1 (fr) * 2015-04-21 2017-05-12 Pf Medicament Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique
CN106243046B (zh) * 2016-08-02 2019-07-05 南京工业大学 一种甲基二磺隆的制备方法
WO2018185266A1 (en) 2017-04-06 2018-10-11 Inventiva New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma.
EP3632908A1 (en) 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
WO2023154412A1 (en) * 2022-02-12 2023-08-17 Miralogx Llc Anti-inflammatory compounds, pharmaceutical compositions, and treatment methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591584A (en) * 1968-08-27 1971-07-06 Pfizer Benzothiazine dioxides
US3808205A (en) * 1971-09-10 1974-04-30 Warner Lambert Co Process for the preparation of 4-hydroxy-3-carbamyl-2h-1,2-benzothiazine 1,1-dioxides and 4-hydroxy-3(2h)-1,2-benzothiazine carboxylate-1,1-dioxides
US4289879A (en) * 1980-09-29 1981-09-15 Pfizer Inc. Synthetic method and intermediate for piroxicam
FR2694295B1 (fr) * 1992-07-28 1994-09-02 Adir Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent.
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
AU2002212672A1 (en) * 2000-10-12 2002-04-22 Dr. Reddy's Research Foundation Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them
GB0224830D0 (en) * 2002-10-24 2002-12-04 Sterix Ltd Compound
JP2006522747A (ja) * 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 縮合１，２，４−トリアゾールの薬学的使用
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
AU2006304434B2 (en) * 2005-10-20 2012-04-05 Merck Sharp & Dohme Corp. Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
BRPI0618885A8 (pt) * 2005-11-21 2018-06-26 Shionogi & Co compostos heterocíclicos tendo atividade inibitória de 11beta-hidroxiesteroide deidrogenase tipo i
JP2007197369A (ja) * 2006-01-26 2007-08-09 Sankyo Co Ltd ベンゾチアジン誘導体

Also Published As

Publication number Publication date
TWI495636B (zh) 2015-08-11
TW201035064A (en) 2010-10-01
CA2753630C (en) 2017-05-30
ES2483516T3 (es) 2014-08-06
AR075777A1 (es) 2011-04-27
TN2011000429A1 (en) 2013-03-27
SG174208A1 (en) 2011-10-28
HK1165802A1 (en) 2012-10-12
GEP20135832B (en) 2013-05-27
MA33138B1 (fr) 2012-03-01
PL2403840T3 (pl) 2014-10-31
EP2403840A1 (en) 2012-01-11
SA110310181B1 (ar) 2013-08-27
AU2010220335A1 (en) 2011-10-13
KR20110122758A (ko) 2011-11-10
NZ595276A (en) 2013-06-28
CA2753630A1 (en) 2010-09-10
CN102341379B (zh) 2015-08-26
IL214907A0 (en) 2011-11-30
EP2403840B1 (en) 2014-05-14
WO2010100139A1 (en) 2010-09-10
BRPI1010243A2 (pt) 2016-03-22
FR2942797A1 (fr) 2010-09-10
AU2010220335B2 (en) 2014-05-29
RU2011139014A (ru) 2013-04-10
CO6501175A2 (es) 2012-08-15
FR2942797B1 (fr) 2011-04-29
ZA201107104B (en) 2012-05-30
IL214907A (en) 2015-02-26
CN102341379A (zh) 2012-02-01
US20110319326A1 (en) 2011-12-29
MY160819A (en) 2017-03-31
JP2012519203A (ja) 2012-08-23
RU2523791C2 (ru) 2014-07-27
US9187438B2 (en) 2015-11-17
UA105040C2 (uk) 2014-04-10
MX2011008942A (es) 2011-09-27
JP5650139B2 (ja) 2015-01-07
KR101701531B1 (ko) 2017-02-01

Similar Documents

Publication Publication Date Title
CL2011002171A1 (es) Compuestos derivados de benzotiazinas, inhibidores de 11beta-hsd1; metodo de preparacion; composiciones farmaceuticas; y su uso para el tratamiento de la diabetes tipo 2, obesidad, dislipidemia, hipertension arterial, ateroesclerosis y ciertos tipos de cáncer.
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
UY28732A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico, procesos para su preparación y su uso como medicamentos.
ECSP088828A (es) 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
EP3699172A3 (en) Novel lipids and compositions for the delivery of therapeutics
ECSP13012967A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
ECSP099382A (es) Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i
UY30094A1 (es) Compuestos químicos
UY29300A1 (es) Compuestos quimicos
CL2012001043A1 (es) Compuestos derivados de hexahidroindenopiridina y/o octahidrobenzoquinolina, inhibidores de 11ß-hidroxiesteroide deshidrogenasa 1 (hsd 1); composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos para la preparacion de medicamentos para el tratamiento de trastornos metabolicos.
CO6541656A2 (es) 2-amino-5.5- difluor-5.6-dihidro-4h-oxazinas como inhibidores de bace1 y/o bace 2
BR112014001468A2 (pt) compostos de tetra-hidropirido-piridina e tetra-hidropirido-pirimidina e uso dos mesmos como modulares do receptor c5a
DK1891038T3 (da) Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
SV2011003842A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
AR075582A1 (es) Compuestos de 4- isopropilfenilglucitol
UY28726A1 (es) N-ciclohexilimidazolinonas sustituidas.procedimientos para su preparación y su uso como medicamentos.
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов&#39;язаних з нею розладів
PA8803201A1 (es) Derivados acidos de cicloalquilamino
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
AR060914A1 (es) Derivados de furopiridina como ligandos receptores de la acetilcolina nicotinica, una composicion farmaceutica que los comprende y su empleo en la manufactura de un medicamento para el tratamiento de una enfermedad mediada por la activacion del receptor alfa7-nicotinico.
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
BRPI0911577B8 (pt) derivados espiro-indol, seus usos no tratamento de doenças parasíticas, e composição farmacêutica